| abstract |
Methods and pharmaceutical compositions comprising low dose farnesyl transferase inhibitors useful in the treatment of proteinosis are provided. These low doses are lower than those used in oncological treatments where these compounds were originally designed for. Treatment includes administering to a patient in need thereof a therapeutically effective amount of a farnesyltransferase inhibitor, wherein this amount is related to farnesylation of a substrate related to Ras or other oncology. It is effective to inhibit farnesylation of non-Ras FTase substrates involved in the autophagy pathway without substantially affecting it. The treatment according to the present invention may further comprise an acetylcholinesterase inhibitor, a neurotrophic receptor activator, an NMDA antagonist, an amyloid deposition inhibitor, a schizophrenia therapeutic agent, an antidepressant, an anxiolytic agent, or an antioxidant. it can. [Selection] Figure 2 |